AEON Biopharma AI Stock Analysis
Want to see AEON full AI Analyst Report?
AEON Biopharma (AEON) AI Stock Analysis
AEON Biopharma
(NYSE MKT:AEON)
AEON Biopharma's overall low score is primarily driven by its high-risk financial profile, characterized by ongoing cash burn, lack of revenue, and overwhelming bearish technical momentum. The stock trades significantly below moving averages and holds unfavorable valuation metrics. However, recent corporate developments provide a modest positive offset, as constructive FDA feedback and fresh capital injections have temporarily stabilized operations and extended the company's financial runway.
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.63M
- Dividend Yield
- ―
- Average Volume (3M)
- 7.70M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.55
- Revenue Growth
- ―
- EPS Growth
- 35.03%
- Country
- US
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum...
How the Company Makes Money
AEON’s primary way to make money would typically be through (a) product sales following regulatory approvals and commercial launch of any therapeutic candidates, and/or (b) licensing, collaboration, and other partnership arrangements (such as upfront...
AEON Biopharma Financial Statement Overview
Summary
AEON Biopharma generates zero revenue and reports persistent net losses alongside significant cash burn. A stockholders' deficit and extremely low total assets highlight elevated solvency risks and a strict reliance on external capital to fund operations.
Income Statement
15Very NegativeBalance Sheet
12Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -39.00K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -25.68M | -16.22M | -27.73M | -52.74M | -52.49M | -36.88M |
| Net Income | -54.62M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | ||||||
| Total Assets | 5.91M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.43M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 2.77M | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 21.27M | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -15.36M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | ||||||
| Free Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -13.64M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | 0 | -4,000 | 0 | 0 | -306.00K | -170.00K |
| Financing Cash Flow | 8.63M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.25, and below the 200-day MA of 0.63, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 30.96 is Neutral, neither overbought nor oversold. The STOCH value of 20.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 62 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAEON Biopharma Peers Comparison
Overall Rating
RNAZ49Neutral- AEON45Neutral
IMNN44Neutral
XTLB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RNAZ | 49Neutral | $22.35M | -0.03 | -58.08% | ― | ― | 86.74% |
| AEON | 45Neutral | $9.04M | -0.04 | 204.18% | ― | ― | 35.03% |
| IMNN | 44Neutral | $4.08M | -0.16 | -349.02% | ― | ― | 67.95% |
| XTLB | 39Underperform | $7.81M | -0.54 | -269.02% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AEON | Aeon Biopharma, Inc. | 0.15 | -0.72 | -82.41% | |
| IMNN | Imunon, Inc. | 0.63 | -3.36 | -84.24% | |
| XTLB | XTL Biopharmaceuticals Ltd. Sponsored ADR | 1.60 | -2.04 | -56.04% | |
| RNAZ | Transcode Therapeutics, Inc. | 1.32 | -8.09 | -85.97% |
AEON Biopharma Corporate Events
AEON Biopharma Amends Warrants With Reduced Exercise Prices
NeutralOn November 2, 2026, AEON Biopharma amended its outstanding Two-Year Warrants, reducing the exercise price for common stock from $0.3221 to $0.20 per share and for Pre-Funded Warrants from $0.3220 to $0.1999 per warrant. The amendment applied to all...
AEON Biopharma Posts Updated Investor Presentation Under Reg FD
NeutralOn October 23, 2026, AEON Biopharma, Inc. made a new corporate presentation available in the investor relations section of its website, providing updated information that management may use in future meetings with investors and other stakeholders. Th...
AEON Biopharma advances ABP-450 biosimilar development strategy
PositiveOn September 30, 2026, AEON Biopharma announced it had received official minutes from its Biosimilar Biological Product Development Type 2b meeting with the U.S. Food and Drug Administration, clarifying the development pathway for ABP-450 as a propos...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026